“Selective Inhibition of Tyrosine Kinase 2 With Deucravacitinib (BMS-986165) Compared With Janus Kinase 1−3 Inhibitors”. 2020. SKIN The Journal of Cutaneous Medicine 4 (6): s108. https://doi.org/10.25251/skin.4.supp.108.